Amlodipine’s effectiveness against SYT4’s oncogenic effects suggests calcium channel modulation as a viable therapeutic strategy in GC, positioning SYT4 as a key biomarker and therapeutic target. This evidence concerns the gene SYT4 and gastric cancer.